Single Source for Chronic Pancreatitis Clinical Research Consortium (CPCRC) Data Coordinating Center (CPCRC-DCC) (U01 Clinical Trial Optional)
ID: 355755Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $1M

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355755

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-020.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Single Source for Chronic Pancreatitis Clinical Research Consortium Data Coordinating Center (CPCRC-DCC)" aimed at supporting the Data Coordinating Center (DCC) for ongoing and new studies related to chronic pancreatitis in both adults and children. This initiative seeks to enhance longitudinal studies focusing on the epidemiological and biological aspects of chronic pancreatitis, with the goal of developing effective treatments and understanding disease progression. The funding, directed exclusively to the University of Texas MD Anderson, amounts to approximately $6.5 million and emphasizes collaborative research, biobank management, and data sharing among consortium members. Interested applicants should note that the application deadline is October 18, 2024, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-020.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DK-25-020-Full-Announcement.html
    RFA-DK-25-020.html
    The National Institutes of Health (NIH), through its National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), has released a funding opportunity titled "Single Source for Chronic Pancreatitis Clinical Research Consortium Data Coordinating Center (CPCRC-DCC)." This initiative aims to continue support for the Data Coordinating Center (DCC) affiliated with the Chronic Pancreatitis Clinical Research Consortium, specifically targeting ongoing and new studies concerning chronic pancreatitis in both adults and children. The funding is directed exclusively to the University of Texas MD Anderson, which has been serving as the DCC since 2015. The new funding cycle will enhance longitudinal studies that focus on the epidemiological and biological aspects of chronic pancreatitis, aiming to develop effective treatments and understand disease progression. Key points include a commitment of approximately $6.5 million for the DCC, emphasizing collaborative research, biobank management for biospecimens, and enhancement of data sharing among consortium members. Application deadlines begin on September 18, 2024, with a total award project period of up to five years. This funding opportunity reflects a non-competitive process vital for fostering comprehensive research efforts regarding chronic pancreatitis.
    Similar Opportunities
    The Chronic Pancreatitis Clinical Research Consortium (CPCRC)- Clinical Centers (CPCRC-CCs) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Chronic Pancreatitis Clinical Research Consortium (CPCRC), inviting U01 applications for Clinical Centers to conduct research on chronic pancreatitis, diabetes, and pancreatic cancer. The initiative aims to continue the consortium's work by collecting clinical data and biospecimens to identify biomarkers for risk stratification and disease progression, ultimately enhancing understanding and treatment of these conditions. With an estimated funding of $6.5 million for the 2025 fiscal year, applications are due by October 18, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Single Source for the Continuation of the Type 1 Diabetes in Acute Pancreatitis Consortium - Data Coordinating Center (T1DAPC-DCC) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is soliciting applications for a cooperative agreement to establish the Type 1 Diabetes in Acute Pancreatitis Consortium Data Coordinating Center (T1DAPC-DCC). The primary objective is to conduct a longitudinal observational study, known as the DREAM study, which will investigate the incidence and mechanisms of diabetes that develop following episodes of acute pancreatitis. This initiative is crucial for understanding the relationship between acute pancreatitis and the onset of diabetes, particularly type 1 diabetes, and aims to identify genetic and environmental risk factors in a diverse population. Interested applicants must submit their proposals by November 19, 2024, with a funding ceiling of $800,000, and can direct inquiries to grantsinfo@nih.gov for further information.
    Limited Competition for the Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers (T1DAPC-CCs) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Limited Competition Funding Opportunity titled "Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers" (T1DAPC-CCs), aimed at establishing a clinical consortium to study diabetes incidence following acute pancreatitis episodes, with a focus on type 1 diabetes. This initiative seeks applications from previously funded Clinical Centers to continue a longitudinal observational study that investigates the incidence, etiology, and risk factors associated with diabetes emerging after acute pancreatitis, emphasizing collaboration among consortium members and effective data collection strategies. The funding amount is capped at $350,000 annually, with a project timeline extending up to five years, and applications are due by November 19, 2024, with the earliest anticipated award start in July 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Central Coordinating Site for the Polycystic Kidney Disease Research Core Centers (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is soliciting applications for the Central Coordinating Site (CCS) for the Polycystic Kidney Disease (PKD) Research Core Centers through Funding Opportunity Number RFA-DK-25-015. The CCS will collaborate with four PKD Research Core Centers to enhance understanding of PKD and promote resource sharing, providing essential administrative support, managing data sharing, and administering pilot project funding. This initiative is crucial for fostering a diverse and collaborative research environment to address the challenges of PKD effectively. The funding opportunity anticipates approximately $1.1 million for one award in FY 2025, with annual budgets around $350,000. Interested applicants must submit their proposals via Grants.gov by November 14, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Coordinating Center for Type 1 Diabetes TrialNet (TNCC) through a cooperative agreement, aimed at supporting research initiatives focused on the prevention and intervention of type 1 diabetes (T1D). The TNCC will manage a variety of research projects, oversee data and sample management, and facilitate the selection of clinical centers necessary for conducting clinical studies related to T1D. This initiative underscores the federal commitment to advancing T1D research and treatment, with a total funding availability of approximately $29.5 million. Interested applicants must submit their proposals by October 17, 2024, and are required to include a Plan for Enhancing Diverse Perspectives (PEDP) as part of their application. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Data Coordinating Center (DCC) for multi-site investigator-initiated clinical trials under funding opportunity PAR-22-193. This initiative aims to support trials that evaluate efficacy, comparative effectiveness, and implementation strategies relevant to the mission of the National Heart, Lung, and Blood Institute (NHLBI), emphasizing collaboration with a Clinical Coordinating Center (CCC). The DCC will be responsible for comprehensive project coordination, data management, and biostatistical support, ensuring adherence to participant safety and diverse population recruitment. Interested applicants must submit both DCC and CCC applications concurrently by September 11, 2025, and can seek early consultation with NIH staff for guidance. For further details, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-193.html.
    Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Silvio O. Conte Digestive Diseases Research Core Centers (DDRCC) program, aimed at enhancing research in digestive and liver diseases. This program seeks to foster collaboration among investigators by providing shared resources that enhance productivity and interdisciplinary research, with proposals required to focus on a central theme related to digestive or liver diseases and demonstrate an existing research base with at least $3 million in annual federal funding. The DDRCC program is critical for promoting integrative research approaches and improving health outcomes in digestive health, with a maximum funding amount of $750,000 in direct costs per year for a project period of up to five years. Applications can be submitted starting January 22, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Single Source for the Continuation of the Human Pancreas Analysis Program (HPAP) for Type 1 Diabetes (HPAP-T1D) (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for a cooperative agreement to support the continuation of the Human Pancreas Analysis Program for Type 1 Diabetes (HPAP-T1D) at the University of Pennsylvania. This initiative aims to enhance research on Type 1 Diabetes by systematically collecting and analyzing human pancreatic tissues and immune cells from patients, thereby advancing the understanding of disease mechanisms and identifying potential biomarkers for early intervention. The program is critical for fostering collaborative translational research within the Human Islet Research Network, which seeks innovative strategies to protect and replace functional human beta cell mass. The total funding available is $7.5 million over four years, with applications due by October 24, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting investigator-initiated, high-risk clinical trials that involve multiple clinical centers. Applicants must propose hypothesis-driven studies that focus on diseases relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with an emphasis on enhancing diverse perspectives in research. This funding opportunity is crucial for advancing therapeutic studies that can significantly improve clinical practices and public health outcomes. Interested applicants should note that the application period opens on January 5, 2024, with a closing date of November 5, 2026, and are encouraged to consult with NIDDK staff prior to submission. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity for high-risk multi-center clinical study implementation planning via Cooperative Agreements (U34). This initiative aims to support the early peer review of proposed clinical studies, assess study designs, and develop essential documentation, including operational manuals, focusing on diseases relevant to NIDDK's mission. The program emphasizes health equity and inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested applicants can apply for up to $225,000 per year for a maximum of two years, with the application submission period opening on September 9, 2024, and the closing date set for June 10, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.